---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-089578"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2023-08-10T23:59:59+00:00"
generated_at: "2026-06-11T18:59:30.346675+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Vaccitech Q2 net loss $23.8M ($0.62 per share); cash $173M extends runway into Q2 2025

## Summary
- Net loss $23.8M, widened from $18.2M in Q1 2023; revenue $0.3M from AstraZeneca royalties.
- R&D expense $13.5M, up from $9.8M Q1, driven by HBV and SNAPvax IND-enabling studies.
- Cash $173M vs $191.3M at Q1; operating cash burn $17M; expects runway into Q2 2025.
- Final HBV002 data presented at EASL; VTP-300 induced HBsAg reductions; interim Phase 2 data expected H2 2023.
- CMO Dr. Margaret Marshall retired July 2023; will remain as consultant.

## SEC filing metadata
- accession: 0001104659-23-089578
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2023-08-10T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000110465923089578/0001104659-23-089578-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000110465923089578/tm2323324d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-089578
- JSON: https://secwatch.observer/filing/0001104659-23-089578.json
- Plain text: https://secwatch.observer/filing/0001104659-23-089578.txt

## Key facts
- Earnings Releases
  Barinthus Biotherapeutics plc. reported second quarter of 2023 results: revenue $0.3 million.
  - Period: second quarter of 2023
  - Revenue: $0.3 million
  - Result: reported results
  source text: plans, we expect our cash runway to fund our operating expenses and capital expenditure requirements into the second quarter of 2025. 2 · Revenue: Revenue consisted of $0.3 million in the second quarter of 2023 compared to $0.5 million in the first quarter of 2023. Revenue was comprised of the Company’s share of royalties received by Oxford University
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828185/000110465923089578/0001104659-23-089578-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.